---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-25-000027"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:04:58.107213+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Akebia posts Q1 2025 net income of $6.1M; Vafseo launch generates $12.0M in net product rev

## Summary
- Total Q1 2025 net product revenues $55.8M, up 80% YoY; Vafseo contributed $12.0M in first quarter of U.S. launch.
- Net income of $6.1M in Q1 2025 versus net loss of $18.0M in Q1 2024; driven by Vafseo and Auryxia sales.
- Auryxia net revenues $43.8M (up from $31.0M YoY); market exclusivity lost March 20, 2025 but no ANDA approved.
- Cash and equivalents $113.4M as of March 31, 2025, up from $51.9M at Dec 31, 2024, after $50M public offering.
- Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD patients in H2 2025.

## SEC filing metadata
- accession: 0001517022-25-000027
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000027/0001517022-25-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000027/akba-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-25-000027
- JSON: https://secwatch.observer/filing/0001517022-25-000027.json
- Plain text: https://secwatch.observer/filing/0001517022-25-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.